Thromboses in children with acute lymphoblastic leukemia

Progress in modern research led to improvement of event-free survival of children with acute lymphoblastic leukemia (ALL), which now reached 80% and higher. Lethal cases today are most often caused by side effects of therapy. Hence, further improvement of the results of ALL treatment in children implies effective prevention and therapy of complications and reduction of the toxicities of therapies. One of hazardous complications of ALL therapy, deteriorating the results of treatment and, hence, the patients’ survival, is thrombosis - life-time blood clotting in the vascular lumen or heart cavities. This paper presents published data on the incidence, pathogenesis, risk factors, diagnosis, and potentialities of modern therapies for this grave complication and its prevention.

дети, острый лимфобластный лейкоз, тромбоз, L-аспарагиназа, тромбофилия, глюкокортикостероиды, центральный венозный катетер, антикоагулянты, низкомолекулярные гепарины, children, acute lymphoblastic leukemia, thrombosis, L-asparaginase, thrombophilia, glucocorticosteroids, central venous catheter, anticoagulants, low molecular weight heparin